| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06917911 Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment… |
Trial sites expanded: 7 -> 14 locations |
| 2026-06-12 | NCT07198074 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin… |
Trial sites expanded: 206 -> 211 locations |
| 2026-06-12 | NCT07061977 Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation… |
Trial sites expanded: 253 -> 260 locations |
| 2026-06-12 | NCT04847453 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or… |
date change Primary completion pushed: 2026-06-30 -> 2028-06-30 |
| 2026-06-12 | NCT04847453 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or… |
date change Completion pushed: 2026-06-30 -> 2028-06-30 |
| 2026-06-12 | NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the… |
date change Primary completion pushed: 2026-04-30 -> 2027-06-30 |
| 2026-06-12 | NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the… |
date change Completion pushed: 2026-04-30 -> 2027-06-30 |
| 2026-06-12 | NCT05691491 Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their… |
Enrollment reduced: 58 -> 42 participants |
| 2026-06-12 | NCT04090398 Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT04090398 Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT02503722 Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal… |
date change Primary completion pushed: 2026-06-05 -> 2027-02-28 |
| 2026-06-12 | NCT02503722 Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal… |
date change Completion pushed: 2026-06-05 -> 2027-02-28 |
| 2026-06-12 | NCT07012044 A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With… |
Trial sites expanded: 2 -> 5 locations |
| 2026-06-12 | NCT04190550 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT04190550 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT05372640 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694… |
date change Primary completion pushed: 2026-06-01 -> 2027-06-07 |
| 2026-06-12 | NCT05372640 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694… |
date change Completion pushed: 2026-06-01 -> 2027-06-07 |
| 2026-06-12 | NCT06179888 Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple… |
Recruitment suspended |
| 2026-06-12 | NCT04044365 Pediatric cGVHD Symptom Scale |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-12 | NCT04044365 Pediatric cGVHD Symptom Scale |
Enrollment reduced: 420 -> 139 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07619521 Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced… | Phase 1/2 | Not Yet Recruiting |
| 2026-06-02 | NCT07619534 Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer… | Not Yet Recruiting | |
| 2026-05-26 | NCT07605416 Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05237947 | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in… | Human Papillomavirus-Related Cervical Carcinoma | Active, Not Recruiting |
| Phase 3 | |||
| NCT04166409 | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With… | Low Grade Astrocytoma | Recruiting |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2… | Endometrial Carcinoma | Recruiting |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard… | Lung Non-Small Cell Carcinoma | Recruiting |
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With… | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recruiting |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy… | Lung Non-Small Cell Carcinoma | Recruiting |
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs… | Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Recruiting |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment… | Anatomic Stage II Breast Cancer AJCC v8 | Recruiting |
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With… | Advanced Lung Non-Small Cell Carcinoma | Recruiting |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of… | Ganglioneuroblastoma, Nodular | Recruiting |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden… | Classic Follicular Lymphoma | Recruiting |
| NCT06422806 | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for… | Metastatic Dedifferentiated Liposarcoma | Recruiting |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus… | Locally Advanced Urothelial Carcinoma | Recruiting |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment… | Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT07061977 | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation… | Locally Advanced Cervical Adenocarcinoma | Recruiting |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin… | Advanced Endometrial Carcinoma | Recruiting |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… | Anatomic Stage II Breast Cancer AJCC v8 | Recruiting |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After… | Clear Cell Adenocarcinoma | Active, Not Recruiting |
| NCT03871257 | A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With… | Low Grade Glioma | Active, Not Recruiting |
| NCT01169337 | Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering… | Light Chain Deposition Disease | Active, Not Recruiting |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | PRETEXT I Hepatoblastoma | Active, Not Recruiting |
| NCT01886872 | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in… | Stage I Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT02443077 | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or… | Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Active, Not Recruiting |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy… | Endometrial Clear Cell Adenocarcinoma | Active, Not Recruiting |